<DOC>
	<DOCNO>NCT01864772</DOCNO>
	<brief_summary>The aim trial evaluate clinical benefit ( efficacy , safety , preservation autonomy ) cetuximab-carboplatin-5FU combination first line treatment recurrent metastatic head neck squamous cell carcinoma patient 70 year without frailty ( geriatric assessment ) .</brief_summary>
	<brief_title>Phase II Trial Carboplatin , 5-FU Cetuximab Elderly Fit ( Frailty ) Patients With Recurrent/Metastatic HNSCC</brief_title>
	<detailed_description />
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age great equal 70 year patient enrol ELANONVOCAL study evaluate fit ( harmonious age ) GERICO screen method geriatric frailty life expectancy superior 12 week creatinin clearance &gt; ou equal 50ml/mn calculate use Modification Diet Renal Disease ( MDRD ) formula hematologic function : absolute neutrophil count &gt; 1.5 x 10^9/l , platelet &gt; 100 x 10^9/l , hemoglobin &gt; 9,5 g/dl liver function : total bilirubin inferior 1,25 x Upper limit normal ( ULN ) , SGOT/SGPT inferior 5 x ULN , PAL inferior 5 x ULN PS &lt; 2 The disease : histologically proven head neck squamous cell carcinoma recurrent metastatic . Visceral metastasis locoregional recurrence unsuitable curative locoregional treatment : unsuitable primitive tumor surgery due local extension ( evidently authorize lymph node ) unsuitable radiotherapy primitive tumor ( already perform ) due metastatic dissemination absence indication reirradiation primitive tumor . Presence least one measurable lesion ( define RECIST criterion ) CT scan IRM asymptomatic cerebral metastasis authorize General : sign Informed Consent Form affiliate French social security system ( beneficiary system ) accord provision law 9 August 2004 Previous systemic chemotherapy , except chemotherapy part multimodal treatment locally advance cancer complete 6 month prior study enrollment Known contraindication specific one study treatment ( particularly cardiac 5FU ) Known dihydropyrimidine dehydrogenase deficiency ( DPD deficiency ) . Patients consider `` unfit `` ( fragile ) GERICO screen method geriatric frailty Irradiation within 4 week prior study enrollment . Nasopharyngeal , rhinopharyngeal maxillary sinus carcinoma . Presence infection ( infection require intravenous antibiotic ) , include tuberculosis HIV infection ( human immunodeficiency virus ) . Concomitant treatment antitumor immunotherapy hormonal therapy . Other antitumor concomitant therapy . Prior treatment EGFRtargeted therapy ( epidermal growth factor receptor ) . Treatment one study drug within 30 day prior study enrollment . Presence document symptomatic brain leptomeningeal metastasis Clinically significant coronaropathy antecedent myocardial infarction within 12 month prior study enrollment highrisk uncontrolled arrhythmias uncontrolled heart failure . Medically uncontrolled arterial hypertension Other prior concomitant cancer , exception carcinoma situ uterine cervix , cutaneous basal cell carcinoma within 5 year prior study enrollment . Presence medical physiological factor susceptible modify patient compliance study protocol followup Informed Consent Form signing . Known allergy hypersensibility monoclonal antibody ( bevacizumab , cetuximab ) , chemotherapy study excipients</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HNSCC</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Elderly</keyword>
	<keyword>Geriatry</keyword>
</DOC>